Zhaohua Zhou, Speaker at Immunogenetics Conferences
Keynote Presentation
Zhaohua Zhou, Food and Drug Administration, United States

Polyethylene glycol (PEG)- modification (PEGylation) is a highly successful strategy for improving the therapeutic properties of protein products. PEGylation increases protein size, inhibits proteolysis and decreases renal filtration, thereby improving the pharmacokinetics (half- [....] » Read More

Matthias Hardtke Wolenski, Speaker at Immunology Conferences
Oral Presentation
Matthias Hardtke Wolenski, Hannover Medical School, Germany

Adoptive immunotherapy with ex vivo expanded, polyspecific regulatory T cells (Tregs) is a promising treatment for graft-versus-host disease. Animal transplantation models used by us and others have demonstrated that the adoptive transfer of allospecific Tregs offers greater prot [....] » Read More

Mohamed Labib Salem, Speaker at Clinical Immunology Conferences
Poster Presentation
Mohamed Labib Salem, Tanta University, Egypt

Cytokine storm, the production of many pro-and inflammatory cytokines such as IL-1, IL-6, and TNF-a, is linked to the severity of illness associated with COVID-19. Several recent studies have found varying levels of inflammatory cytokines in COVID-19 patients' plasma, primari [....] » Read More

Alec Bigness, Speaker at Clinical Immunology Conferences
Poster Presentation
Alec Bigness, University of South Florida Morsani College of Medicine, United States

Introduction Highly active antiretroviral therapy (HAART) has substantially reduced the prevalence of Kaposi Sarcoma (KS),1,2 yet its effectivity has rendered a new phenomenon, KS-IRIS, a serious condition where patients experience paradoxical worsening after HAART initiation th [....] » Read More

Laura Elisa Buitrago Molina, Speaker at Immunology Conferences
Poster Presentation
Laura Elisa Buitrago Molina, Hannover Medical School, Germany

Autoimmune hepatitis (AIH) is a chronic autoimmune inflammatory disease that usually requires life-long immunosuppression. Frequent relapses after discontinuation of therapy indicate that intrahepatic immune regulation is not restored by current therapies. As steroid therapy pref [....] » Read More

Lissete Sanchez Magraner, Speaker at Immunotherapies Congress
Oral Presentation
Lissete Sanchez Magraner, Fast Base solutions, Spain

Non–small cell lung carcinoma (NSCLC) is known to evade host immune defenses via a downregulation of the immune response. One of the molecules involved in this mechanism is programmed cell death ligand 1 (PD-L1), which interacts with its receptor, programmed cell death prot [....] » Read More